Related Experiment Videos
An antiproliferative bioassay for interleukin-4
1Division of Immunobiology, National Institute for Biological Standards and Control, Potters Bar, Herts. UK.
Abstract:
Interleukin-4 (IL-4) is currently being used for therapeutic intervention in a wide range of malignant diseases as an antitumour agent. Although bioassays have been developed that measure the proliferative capacity of IL-4, none measure the antiproliferative activity of this molecule. We have developed a simple, sensitive bioassay for human IL-4 based on the ability of this cytokine to inhibit the proliferation of the human lung carcinoma line, CCL-185, an easy to maintain, cytokine independent, cell line. It is rapid, reproducible and sensitive, able to detect 2 pg/ml IL-4. The assay is completely unresponsive to all other interleukins from IL-2 to IL-12, to the colony stimulating factors and transforming growth factor beta and is 100-fold less sensitive to interferon-alpha, tumour necrosis factor-alpha, IL-1 beta and IL-13. The assay can be made completely specific for IL-4 by including specific neutralizing antibodies for IL-4 and is suitable for the estimation of IL-4 in both plasma and serum samples.
Insights
A new bioassay detects the antiproliferative effects of Interleukin-4 (IL-4) in cancer. This sensitive method quantifies IL-4 in plasma and serum, aiding cancer therapy research.
Area of Science:
- Biotechnology
- Immunology
- Oncology
Background:
- Interleukin-4 (IL-4) shows therapeutic potential as an antitumour agent in various cancers.
- Existing bioassays primarily measure IL-4's proliferative capacity, not its antiproliferative activity.
Purpose of the Study:
- To develop a sensitive and specific bioassay for quantifying the antiproliferative activity of human Interleukin-4 (IL-4).
- To establish a reliable method for measuring IL-4 in biological samples like plasma and serum.
Main Methods:
- Utilized the human lung carcinoma cell line CCL-185, which is cytokine-independent and easy to maintain.
- Developed a bioassay based on IL-4's ability to inhibit CCL-185 cell proliferation.
- Assessed assay specificity against other interleukins (IL-2 to IL-12), colony-stimulating factors, TGF-β, IFN-α, TNF-α, IL-1β, and IL-13.
Main Results:
- The developed bioassay is rapid, reproducible, and highly sensitive, detecting IL-4 down to 2 pg/ml.
- The assay demonstrated minimal cross-reactivity with other tested cytokines and growth factors.
- Complete specificity for IL-4 was achieved by incorporating neutralizing antibodies.
Conclusions:
- A novel, sensitive bioassay for human IL-4's antiproliferative activity has been successfully developed.
- This assay provides a valuable tool for measuring IL-4 in clinical samples, supporting its therapeutic applications in oncology.
- The assay's specificity and sensitivity make it suitable for research and potential clinical diagnostics.